Brexit Archives -

Leela Barham and Neil Grubert look back at what was expected for market access in 2021 and look

How do UK market access prospects look in 2022?

https://pharmaphorum.com/market-access-2/uk-market-access-prospects-2022/

Why we need the human element of remote clinical trials

News/ News/ Patients

MHRA seeks comments on post-Brexit clinical trial legislation

Phil Taylor Brexit, clinical trials, MHRA, regulatory 0 Comment

The MHRA has kicked off an eight-week consultation on proposals for changes to laws governing the conduct of

MHRA seeks comments on post-Brexit clinical trial legislation

https://pharmaphorum.com/news/mhra-seeks-comments-on-post-brexit-clinical-trial-legislation/

Market Access/ Views & Analysis/ Views and analysis

Post-Brexit medicines regulation must have international scope

Amanda Barrell ABPI, Brexit, regulatory frameworks 0 Comment

Post-pandemic, post-Brexit Britain must create a regulatory framework that both defines and aligns with international standards, or risk

Post-Brexit medicines regulation must have international scope

https://pharmaphorum.com/market-access-2/post-brexit-medicines-regulation-must-have-international-scope/

Market Access/ News/ News

MHRA cuts could affect UK regulatory decisions, say unions

Phil Taylor Brexit, MHRA, regulatory, workforce 0 Comment

A 20% to 25% reduction in staffing at the UK Medicines and Healthcare products Regulatory Agency (MHRA) risks

MHRA cuts could affect UK regulatory decisions, say unions

https://pharmaphorum.com/news/mhra-cuts-could-affect-uk-regulatory-decisions-say-unions/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Deep Dive: Market Access

mike.hammerton@pharmaphorum.com Boehringer Ingelheim, Brexit, Deep Dive, digital health, HTA, market access, NICE, patient centricity, patient engagement, sales 0 Comment

It’s fair to say this is the most interesting time ever for market access. Not only has COVID

Deep Dive: Market Access

https://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access-2021/

Market Access/ Views & Analysis/ Views and analysis

The Brexit deal; shot in the arm or kick in the teeth for the pharma sector?

Catherine Longworth Brexit, EU 0 Comment

The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as

The Brexit deal; shot in the arm or kick in the teeth for the pharma sector?

https://pharmaphorum.com/market-access-2/the-brexit-deal-for-the-pharma-sector/

News/ News/ R&D

UK chancellor Sunak urged to boost pharma and biotech in budget

Richard Staines Biotech, Brexit, budget, investment, R&D, Rishi Sunak 0 Comment

UK chancellor Rishi Sunak has been urged to recognise the leading role that pharma companies are playing in

UK chancellor Sunak urged to boost pharma and biotech in budget

https://pharmaphorum.com/news/uk-chancellor-sunak-urged-to-boost-pharma-and-biotech-in-budget/

News/ News/ Sales and Marketing

UK parliament backs EU trade deal, as industry sifts through detail

Phil Taylor ABPI, BIA, Brexit, EFPIA, EU, trade, UK 0 Comment

The post-Brexit trade deal agreed on Christmas Eve has been overwhelmingly backed by the UK parliament, providing some

UK parliament backs EU trade deal, as industry sifts through detail

https://pharmaphorum.com/news/uk-parliament-backs-eu-trade-deal-as-industry-sifts-through-detail/

United Kingdom withdrawal from the European Union

News/ News/ Patients

NHS leaders urge UK government to extend Brexit transition period

Catherine Longworth Brexit, COVID-19, European Union, NHS Confederation 0 Comment

NHS leaders have written to the UK prime minister urging him to extend the Brexit transition period by

NHS leaders urge UK government to extend Brexit transition period

https://pharmaphorum.com/news/nhs-uk-extend-brexit-transition/

Trending

Brexit

Login